Published: 30 July 2014
Author(s): Antonio Tursi, Walter Elisei, Marcello Picchio, Antonio Penna, Piera Giuseppina Lecca, Giacomo Forti, GianMarco Giorgetti, Roberto Faggiani, Costantino Zampaletta, Giorgio Pelecca, Giovanni Brandimarte
Infliximab (IFX) is the key treatment for ulcerative colitis (UC) unresponsive to standard treatments. The aim of the present study was to assess the efficacy and safety of IFX in treating ambulatory UC patients in primary gastroenterology centers.
